English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without  epidermal growth factor receptor  mutation and  anaplastic lymphoma kinase  rearrangement.    Methods  Patients with pretreated advanced non‐small‐cell lung cancer without  epidermal growth factor receptor  mutation and  anaplastic lymphoma kinase  rearrangement were included. The patients were administered 100 mg/m 2  of nanoparticle albumin‐bound paclitaxel on days 1, 8, 15 and 22 (level 0) or on days 1, 8 and 15 (level –1) every 4 weeks during phase I of the trial. The primary endpoint was objective response rate. The estimated objective response rate was 15% and the threshold was 5% with an  α  error of 0.05 and  β  error of 0.2 in phase II.    Results  The recommended schedule was determined as level –1 in phase I. The characteristics of the 55 patients enrolled in phase II were as follows: median age = 66 years, male/female = 40/15, second/third line = 34/21 and adenocarcinoma/squamous cell carcinoma/large cell carcinoma/others = 34/17/2/2. Objective response rate was 7.3% (95% confidence interval, 2.0–17.6%). Median progression‐free survival was 3.4 months. Treatment‐related grade 3 or 4 toxicities were neutropenia (36.4%), febrile neutropenia (5.5%) and pulmonary infection (3.6%). Three patients had grade 2 pneumonitis and one treatment‐related death occurred due to adult respiratory distress syndrome.    Conclusion  This study failed to meet predefined primary endpoints for pretreated patients with advanced non‐small‐cell lung cancer without  epidermal growth factor receptor  mutation and  anaplastic lymphoma kinase  rearrangement.

asia‐pacific journal of clinical oncology

A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without  epidermal growth factor receptor  mutations and  anaplastic lymphoma kinase  rearrangement